Abstract
Parkinsons disease is a neurodegenerative disorder characterized by a progressive neuronal loss affecting preferentially the dopaminergic neurons of the nigrostriatal projection. Transplantation of fetal dopaminergic precursor cells has provided the proof of principle that a cell replacement therapy can ameliorate clinical symptoms in affected patients. Recent years have provided evidence for the existence of neural stem cells with the potential to produce new neurons, particularly of a dopaminergic phenotype, in the adult mammalian brain. Such stem cells have been identified in so called neurogenic brain areas, where neurogenesis is constitutively ongoing, but also in primarily non-neurogenic areas, such as the midbrain and the striatum, where neurogenesis does not occur under normal physiological conditions. We review here presently published evidence to evaluate the concept that endogenous neural stem cells may have the potential to be instrumentalized for a non-invasive cell replacement therapy with autologous neurons to repair the damaged nigrostriatal dopaminergic projection in Parkinsons disease.
Keywords: Parkinson's disease, neurogenesis, stem cells, dopamine, cell therapy, regenerative medicine
CNS & Neurological Disorders - Drug Targets
Title: Adult Neurogenesis and Parkinsons Disease
Volume: 6 Issue: 5
Author(s): Oscar Arias-Carrion, Nils Freundlieb, Wolfgang H. Oertel and Gunter U. Hoglinger
Affiliation:
Keywords: Parkinson's disease, neurogenesis, stem cells, dopamine, cell therapy, regenerative medicine
Abstract: Parkinsons disease is a neurodegenerative disorder characterized by a progressive neuronal loss affecting preferentially the dopaminergic neurons of the nigrostriatal projection. Transplantation of fetal dopaminergic precursor cells has provided the proof of principle that a cell replacement therapy can ameliorate clinical symptoms in affected patients. Recent years have provided evidence for the existence of neural stem cells with the potential to produce new neurons, particularly of a dopaminergic phenotype, in the adult mammalian brain. Such stem cells have been identified in so called neurogenic brain areas, where neurogenesis is constitutively ongoing, but also in primarily non-neurogenic areas, such as the midbrain and the striatum, where neurogenesis does not occur under normal physiological conditions. We review here presently published evidence to evaluate the concept that endogenous neural stem cells may have the potential to be instrumentalized for a non-invasive cell replacement therapy with autologous neurons to repair the damaged nigrostriatal dopaminergic projection in Parkinsons disease.
Export Options
About this article
Cite this article as:
Arias-Carrion Oscar, Freundlieb Nils, Oertel H. Wolfgang and Hoglinger U. Gunter, Adult Neurogenesis and Parkinsons Disease, CNS & Neurological Disorders - Drug Targets 2007; 6 (5) . https://dx.doi.org/10.2174/187152707783220875
DOI https://dx.doi.org/10.2174/187152707783220875 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Updates of N-Type Calcium Channel Blockers with Therapeutic Potential for Neuropathic Pain and Stroke
Current Topics in Medicinal Chemistry Past, Present and Future Therapeutics for Cerebellar Ataxias
Current Neuropharmacology Nox Inhibitors & Therapies: Rational Design of Peptidic and Small Molecule Inhibitors
Current Pharmaceutical Design Vitamins and Cognition: A Nutrigenomics Perspective
Current Nutrition & Food Science Editorial (Hot Topic: Coming Back to Nature: Plants as a Vital Source of Pharmaceutically Important Metabolites – Part II B)
Current Medicinal Chemistry Neuroprotective Potential of Adenyl Cyclase/cAMP/CREB and Mitochondrial CoQ10 Activator in Amyotrophic Lateral Sclerosis Rats
Current Bioactive Compounds Selective COX-1 Inhibition: A Therapeutic Target to be Reconsidered
Current Medicinal Chemistry Myelin Sheaths and Autoimmune Response Induced by Myelin Proteins and Alphaviruses. I. Physicochemical Background
Current Medicinal Chemistry C-Peptide and its Correlation to Parameters of Insulin Resistance in the Metabolic Syndrome
CNS & Neurological Disorders - Drug Targets Single Nucleotide Polymorphisms (SNPs): History, Biotechnological Outlook and Practical Applications
Current Pharmacogenomics Tetracyclines and Neuromuscular Disorders
Current Neuropharmacology Autophagic Dysfunction in Dementia: Scope for Development of Potential Remedies
CNS & Neurological Disorders - Drug Targets Ethical Implications for Clinical Practice and Future Research in “At Risk” Individuals
Current Pharmaceutical Design Transthyretin Deposition in Familial Amyloidotic Polyneuropathy
Current Medicinal Chemistry Neuroprotection by Resveratrol in Diabetic Neuropathy: Concepts & Mechanisms
Current Medicinal Chemistry Differences in Relative Levels of 88 microRNAs in Various Regions of the Normal Adult Human Brain
MicroRNA Localisation of Endothelin-1 and its Receptors in Vascular Tissue as Seen at the Electron Microscopic Level
Current Vascular Pharmacology Conformational Diseases and ER Stress-Mediated Cell Death: Apoptotic Cell Death and Autophagic Cell Death
Current Molecular Medicine In Vivo DNA Electrotransfer for Immunotherapy of Cancer and Neurodegenerative Diseases
Current Drug Metabolism The Involvement of Post-Translational Modifications in Alzheimer's Disease
Current Alzheimer Research